The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be immediately reimbursed and when any reimbursement should be withheld while awaiting more evidence. This framework assesses the value of obtaining additional evidence to inform a current reimbursement decision. This represents the burden of not having the additional evidence at the time of the decision. However, when deciding whether to reimburse now or await more evidence, decision makers need to know the value of investing in more research to inform a future decision. Assessing this value requires consideration of research costs, research time, and what happens to patients while the research is undertaken and after completion. The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy.
The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be immediately reimbursed and when any reimbursement should be withheld while awaiting more evidence. This framework assesses the value of obtaining additional evidence to inform a current reimbursement decision. This represents the burden of not having the additional evidence at the time of the decision. However, when deciding whether to reimburse now or await more evidence, decision makers need to know the value of investing in more research to inform a future decision. Assessing this value requires consideration of research costs, research time, and what happens to patients while the research is undertaken and after completion. The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy. Key words: Bayesian decision theory, expected value of information, research design, cost-effectiveness analysis. (Med Decis Making 2012; 32:E11-E21) I nstitutions responsible for the financing of health care must decide whether to adopt a new therapy. Such a decision will rest on the expected costs and expected benefits of an adoption decision in light of current evidence and the size of the available budget. Value of Information Analysis has been proposed as a method for informing choices between providing coverage for new therapies and awaiting further information to reduce the risk of making the wrong decision. 1, 2 However, conventional Expected Value of Sample Information (EVSI) is a measure of the burden of decision uncertainty at the point in time when the decision has to be made. It is not a measure of the value of investing in research to reduce that uncertainty.
The conduct of further research has consequences in terms of resources invested. It also delays a final or revised adoption decision, the consequences of which may be either the denial of an effective therapy to patients or the suboptimal investment in an inappropriately adopted therapy. Three important determinants of the value of investing in research are therefore missing from the standard EVSI model: 1) time that it takes for the research to report, 2) the uncertainty around the time it will take to report (e.g., uncertain recruitment rate into a study), and 3) the costs and outcomes of patients while the research is undertaken and once it has been reported. Eckermann and Willan have considered some of these issues but not in the context of multiparameter decision analytic modeling. [3] [4] [5] They take a parametric approach, which relies on the availability of individual patient data that must be considered adequate to inform the decision problem in its entirety. McKenna and Claxton considered Determinants 1 and 3 within a decision modeling framework, allowing the synthesis of all available sources of evidence, but there is a need to incorporate Determinant 2 into their approach and the consequent significant differences in the analytical method. 6 There is also a need to expand on the limited number of worked examples in the literature.
The standard formulation of EVSI is outlined below. In the methods section we describe a development of the expected value of sample information framework that incorporates all these missing factors. The enhanced framework is extended to show how it can be used to address questions such as the relative value of only-in-research (OIR) v. only-with-research (OWR) reimbursement decisions. Such conditional decisions are accepted as a variation on an emphatic decision whether to adopt a new therapy. In the absence of adequate evidence they provide an incentive for further research with an opportunity to revise a decision in light of future evidence development. 7 To differentiate between the conventional EVSI calculation and our new specification of the value of investing in further research, we refer to the value of investment in further research as the Expected Net Present Value of Sample Information (ENPVSI).
EXPECTED VALUE OF SAMPLE INFORMATION: CURRENT METHOD
A decision to adopt a new intervention within a portfolio of interventions funded from a fixed health care budget will result in reallocation of resources from an alternative intervention (or standard care). Such a decision is optimal if the new intervention provides greater net benefit (in terms of cost or health gain), given a specified willingness-to-pay (WTP) threshold, than that provided by a displaced intervention. Where this decision relies on uncertain evidence there will be a risk of making an incorrect allocation decision. By definition, an incorrect decision will result in a lower overall net benefit and from this derives the value in reducing this decision uncertainty.
A decision relies on a number of uncertain parameters u, for which the current evidence p(u) defines a multivariate probability distribution. The EVSI represents the expected payoff from conducting further research into a subset of parameters (or single parameter) of interest u I . The conceptual framework within which an EVSI calculation lies applied to the health care lies is introduced in detail by Claxton. 1 The calculation of EVSI relies on the Bayesian updating of the uncertain distribution of u I on the basis of an increasing notional sample size for research, further informing u I . The value attributable to the reduction in decision uncertainty is calculated by subtracting the expected net benefit with current information from the expected net benefit with the information from the notional sample. This is typically calculated as the EVSI per patient. For a technical guide to the calculation of EVSI, see Ades and others. 5 To calculate the total EVSI for a population served by a health care budget, the accepted method is to multiply the per-patient EVSI by the number of patients for whom the intervention is indicated. This should take into account the expected time over which the intervention is useful and the reimbursement decision is pertinent; a suitable discount rate should also be applied. As further research takes place, a number of patients will be directly affected as participants in the research sample. A portion of these may be treated with the current standard of care, whereas a proportion will be treated with the interventions under investigation. All others will be treated with the treatment or strategy believed optimal at the time the patient presents to the health care provider.
If there are j alternative interventions with uncertain parameters u (current evidence), the optimal treatment strategy that maximizes net benefit (NB) for the expected mean of u achieves: Expected Net BenefitjCurrent Information5max j E u NBðj; uÞ;
Where E z ½f ðzÞ5 R f ðzÞpðzÞdz is the expectation of function f averaged over values taken by random variable z. Now, consider a particular research study that might provide new data relating to a subset of parameters of interest u I . The data X u I obtained from a proposed study will update our knowledge concerning the parameters of interest u I . It is this process of updating the probability distributions p(u) given new data X u I that make EVSI inherently Bayesian. If parameters are correlated, the additional information about u I may additionally tell us something about the complementary set of parameters u c I , that is, u5ðu I ; u c I Þ. If we imagine we have obtained data X u I , then it is reasonable to make a revised decision based on our updated prior information. This will lead us to choose the treatment with the highest expected net benefit now given the data. This expectation is taken over the joint posterior density of u I jX u I and can be written as, max j E u c I ;u I jX u I NBðj; u I ; u c I Þ: If u I and u c I are independent, then this expectation is taken over the prior density of u c I , and the posterior density of u I given X u I :
As yet we do not know what the result of the proposed collection of data X u I will be. Thus, to calculate the expected value of a decision made after data have been collected, we must take an expectation over the density of X u I , giving E X u I ½max j E u c I ;u I jX u I NBðj; u I ; u c I Þ: Finally, the standard form for the expected value of sample information is the difference between the expected value of a decision made after data X u I have been collected and expected value of a decision made now, with only current information. That is,
This provides the EVSI for a single patient at a given point in time. It also makes the assumption that the additional information to be obtained from the sample is available instantaneously. The accepted calculation for extrapolating to the EVSI for the population for whom the decision is pertinent is given by
where N is the number of people taking part in research when obtaining further information, T is the time over which the decision is pertinent, I t is the disease incidence over time interval t, and r is the discount rate. When calculating the population EVSI, the benefit is only assessed over those whose treatment could be affected by the additional information ðI t À NÞ
METHODS

Expected Net Present Value of Sample Information
To inform the decision of whether to invest in research to reduce the decision uncertainty, it suffices to assess whether the costs of investing in the research over time are justified by the expected present value of the information becoming available at an uncertain future point in time, t. As before, the research would provide data X u I and update parameter values from the prior u to the posterior ujX u I .
The purpose of a study is to obtain more information about the impact of alternative treatments and incurred costs in both a financial and a health sense. The health impact can be assessed according to the therapies received between the time of the decision to invest in the research and the time when the research reports. By the nature of any comparative research, at least some individuals must receive treatments determined to be less efficient once the research has reported. This holds irrespective of whether those individuals were actively involved in the research. The value of the research consists of the reduction in the expected cost of making the wrong decision based upon current evidence compared with the expected cost of making the wrong decision based upon the updated evidence that will be available once the research has reported.
Both the costs of the research and the value of the research need to be discounted to reflect that the new information and any change in the reimbursement decision will occur at an uncertain point in the future. Therefore, to accurately capture the expected net present value of sample information, it is necessary to model the following: To do this, it is necessary to incorporate a trial simulation model into the standard expected value of sample information to represent the uncertain estimate for the time for research to take place (t). This is likely to depend on a number of uncertain factors, including the expected effectiveness of each strategy (comparator) and the baseline rate of the event of interest where clinical outcomes are time-dependent, the uncertain time to set up research, and an uncertain recruitment rate. It may also incorporate a risk that research will not complete at all.
If we consider a research design comparing standard care with a single intervention in a 2-arm randomized controlled trial, the assessment of net benefit over time needs to consider the per-patient NB in each of 4 groups of patients, multiplied by the number of patients over the relevant time period for each group. The ENPVSI will be the combination of the expected NBs of these groups of patients ( Figure 1 Constraints are placed on those patients for whom the disease is incident prior to the time research reports, such that the choice of treatment may be constrained by inclusion in one arm of the trial. The expected net benefit for the patients in the trial may be read out from the simulated trial result on the basis of the notional sample size.
Given that the health impacts of inefficient treatment may only be evident after the research has concluded, the expected net benefit for patients out-with the research remains uncertain until the research reports. However, these patients have their treatment allocated according to the information available before the trial reports-that is, subject to the specific decision rules employed by the decision maker at time zero. At time zero, the decision maker is not constrained to require that patients out-with the trial receive the treatment that is currently deemed costeffective. Instead, the decision maker can consider cases in which approval for new interventions are given either OIR or the intervention is adopted conditional on research taking place (OWR); the ENVPSI framework incorporates both options, alongside the standard assumption that patients treated out-with the trial are treated with the option currently considered most cost-effective.
The expected net present value of sample information when comparing J treatments is given by the following:
where, assuming that u I and u I c are independent,
where n t = number of patients in trial during time interval t, j = trial arm or intervention j, t = time for further sampling (time for research to report), and T = time over which decision is pertinent. Figure 1 Diagrammatic presentation of calculation of net benefit from sample information. This will depend on whether the strategy with the highest net benefit is used or whether this is constrained by an only-in-research or only-with-research arrangement.
The Monte Carlo sampling algorithm for implementation as a 2-level simulation is outlined in the appendix.
RESULTS
Exemplar Model: A New Treatment for Early Breast Cancer
We consider the cost-effectiveness of a new targeted antibody treatment called bevacizumab for triple negative early breast cancer (TNBC). This is a hypothetical decision context that looks at a reimbursement decision to be made at a hypothetical time point prior to a Phase III trial reporting. TNBC is a subtype of breast cancer where the tumor cells are negative for overexpression of 3 cell-surface proteins-estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2. Treatment takes place over 1 year, starting immediately after surgical resection of a primary breast cancer, concurrently with chemotherapy. There is a short (3-month) window after surgery during which treatment is indicated and the condition can be considered temporarily prevalent. After this window there is no further opportunity to treat. The comparator is standard care.
A time-dependent state transition cohort model is used to estimate incremental costs and effects between standard care and the addition of the new drug. Parameter uncertainty is examined using probabilistic sensitivity analysis via Monte Carlo simulation. The rationales for model structure, underlying assumptions, parameterization, and parameter distributions have been discussed elsewhere in a similar model assessing trastuzumab for early breast cancer. 8 The model used here is a simplified version adapted to the decision context for illustration only. In particular, as there is not a randomized comparison to provide an estimate of efficacy of bevacizumab in this context, this (the log-hazard ratio for disease free survival) has been derived from discussion with clinical experts. In a formal economic evaluation, a structured elicitation exercise would be desirable to populate this parameter.
The model is used as the basis to determine the ENPVSI of a proposed randomized controlled trial comparing standard care with bevacizumab. In this hypothetical trial design, 2000 patients are randomized between 2 arms. The primary outcome measure (specified in classical terms) is disease-free survival whereby 388 events are required by the prespecified power calculation. The proposed trial will only inform the hazard ratio for disease free survival and therefore this is the parameter of interest u I with all other parameters in Table 1 comprising u c I . This example has been chosen because the time to trial report is particularly important due to the high cost of clinical trials in early breast cancer and the particular unmet therapeutic need in TNBC. As the final analysis of the primary outcome is dependent on reaching a predefined number of events, its timing is not only uncertain but is also dependent on the hazard ratio u I and the underlying event rate (within u c I ). It is in fact possible that the trial will not report at all within the useful lifetime of the drug; in this case the expected net benefit for all patients would default to the case where no research was planned and the ENPVSI would be negative.
Model Summary
The model consists of 5 states: disease free, local recurrence, disease free after local recurrence, distant recurrence, and death (see Figure 2 ). We calculate mean costs and QALYs for a hypothetical cohort of women with triple negative breast cancer of average age 50 (N = 2000). The model has an annual cycle and a 50-year time horizon, by which point all patients have died. The analysis is undertaken from the perspective of the UK National Health Service.
The model parameters are transition probabilities, costs and utilities. The specification and evidence base for each parameter is reported in Table 1 .
Trial Simulation Model to Estimate the Time for Research to Report (t)
A clinical trial testing a new adjuvant breast cancer therapy will typically rely on a time-dependent primary outcome measure such as progression-free survival. In this example t represents the time between the opening of the trial and the reporting of the final event required for analysis. This time interval is calculated using a trial simulation model with timedependency-here a simple time-dependent statetransition model is used with a cycle length of one month. The model structure is shown in Figure 3 and the transition matrix is shown in Table 2 .
There are 5 states in the model: State A contains patients recruited from the incident population at monthly intervals. These patients can then transit, by randomization to either state B (control intervention arm) or State C (investigational intervention arm). A certain proportion of patients in both arms will be lost to follow-up (State D) and therefore will not provide event data to the study, and a certain proportion of patients in both arms will experience outcome events (State E). Monte Carlo simulation is used to sample from uncertain input trial parameters, producing as an output the distribution for t, where t is defined as the time from commencement of the trial until the trial reports. Uncertain parameters include the monthly probability of a progression event (p), the hazard ratio for progression free survival between a control arm and an intervention arm (HR), a sample size (N), a vector of monthly recruitment (x t ), and a monthly rate of loss to follow-up (f). The distribution of t from this model is shown in Figure 4 .
The Expected Time to Trial Report parameter t is incorporated into the ENPVSI calculation for a proposed trial of 2000 patients randomized between 2 treatments (n = 1000 in each arm) to generate additional evidence only on the effectiveness (hazard ratio) of a new treatment for TNBC, in 3 frameworks:
1. The ENPVSI when the new treatment is available to patients outside the trial only if it represents the most cost-effective treatment strategy prior to the trial commencing 2. The ENPVSI when the new treatment is only available within the trial (OIR) 3. The ENPVSI when the new treatment is adopted for all patients outside of the trial regardless of baseline estimates of cost-effectiveness For comparison, the conventional population Expected Value of Sample Information is also reported.
These analyses will allow the exploration of (a) the potential impact of using the expected net present value of sample information rather than the expected value of sample information to assess the value of further research and (b) the ability of the ENPVSI framework to compare the value of OIR v. OWR approaches to addressing decision uncertainty in the reimbursement setting.
Model Outputs: EVSI v. ENPVSI
The expected incremental cost effectiveness ratio at baseline (i.e., based on current information) is reported in Table 3 . The incremental costeffectiveness ratio (ICER) is around £90,000 and therefore beyond the level at which a therapy would normally be approved for funding by NICE. However, as a breast cancer therapy likely to be associated with a strong patient lobby, it is credible that there would be significant pressure for the treatment to be made available, at least within research. Figure 5 plots the conventional measurement of the expected value of sample information, the EVSI, and the ENPVSI. Note that it is the population value of information that is reported, as the concept of individual ENPVSI cannot be captured in a single number: whether the individual is involved in the research determines how his or her health is assessed. We can see that for some WTP thresholds, the ENPVSI is negative whereas the EVSI does not fall below zero. This reflects the fact that research that would not change the decision and so has resource implications but no value.
When the ENPVSI is positive, the EVSI is higher indicating that the burden of limited information overstates the return on investment in obtaining that information. This would be the case even if the cost of the research were zero, as the ENPVSI includes the discounted value of information becoming available in the future. Figure 6 shows the ENPVSI for the trial when the treatment is only available to patients involved in the research (OIR) and the ENPVSI when the treatment is available to all patients outside of the trial while the research is completed (OWR). It shows clearly that an OWR approach produces negative health benefits until the WTP threshold is around £60,000, whereas the OIR produces positive health benefits for WTP thresholds above £45,000. As the WTP threshold increases beyond the expected ICER, the value of OIR falls rapidly, reflecting the greater value attached to the health foregone while waiting for the research to report, whereas the value of OWR reduces much more slowly.
Only in Research v. Only with Research
DISCUSSION
The Expected Value of Information Framework has been proposed to identify when health care technologies should be immediately reimbursed and when reimbursement should be withheld while awaiting (Note: patients outside the clinical trial are treated with the strategy offering the highest net benefit. For willingness-to-pay \£90,000 per QALY this is standard care, and otherwise it is the intervention.) more evidence. The standard expected value of information framework assesses the value of having additional evidence available to inform a current decision. This can be thought of as the burden of not having the additional evidence available at the time of the decision. However, the information that decision makers need to decide whether to reimburse now or await more evidence is the value of investing in the creation of the new evidence to inform a future decision. Assessing this value requires the analysis to incorporate the costs of the research, the time it will take for the research to report, what has happened to patients while the research is undertaken, and what will happen once it has reported. In this article we have shown how the standard approach to estimating expected value of sample information can be extended to incorporate these factors. This suggests that the standard expected value of sample information calculations will overestimate the value of additional research because the EVSI does not fully incorporate opportunity costs incurred for those allocated to a suboptimal treatment strategy within the research. Eckermann and Willan have described a closedform model for estimating expected value of information analysis that takes account of how long it takes the research to report. Our framework develops these insights for incorporation in a decision analytic modeling framework. 5, 9 We have shown how this framework can be used to examine the relative value of OIR and OWR approaches to generate more evidence. Importantly, the analyses will allow the explicit quantification of the health gain foregone by patients denied access to a therapy until the research is completed (OIR) and health gain foregone by other patients when a therapy is reimbursed that is subsequently found to be insufficiently effective (OWR).
Our framework incorporates conventional clinical trial simulation modeling into the decision analytic cost-effectiveness framework, bridging 2 complementary but historically independent approaches to research optimization. Given the increasing importance of reimbursement decisions to regulatory trial design considerations, 10 this is a potentially important demonstration of the intellectual link between these 2 endeavors. Predicting the time for research to report has always been a high priority and particularly so in the case of expensive Phase III drug trials. In the public arena this is a consequence of a desire to minimize the delay for patients in accessing new treatments. In an industry setting, prolonging research often means lost revenue. It therefore seems essential that an estimate of the duration of research be incorporated into value of information analysis if it is to find real-world applications. This will be particularly important where the proposed research is either large or time consuming, as will often be the case in the context of early cancer, where absolute gains may be small and occur over a long time.
There are many uncertainties in the evidence base for any decision, and the value of research to reduce these uncertainties can differ substantially. 11 Our framework suggests that conventional assessments of value of information that do not take account of the time it takes for research to report and the costs and outcomes of patients while the research is completed, produce incorrect estimates of the relative value of different research studies. In addition, incorporating the differential time for different types of research to report will affect the assessment of the value of sequential research designs. Discounting implies that quicker research has a higher value, which will also affect the residual value of further research on other parameters in the decision problem. We hypothesize that efficient sequential research designs would incorporate stopping rules for later studies based upon the results of earlier studies in the research process and that the optimal ordering of studies within sequential designs will depend heavily upon the time it takes for the research to report and the (as-yet unmodeled) delays while studies are analyzed. 12 The constituent parts of Formula 3 rely on the expected net benefit for the patients in each group.
The choice of which expectation should be used for each deserves some consideration. Patients allocated to participate in proposed research are synonymous with the notional sample size used for Bayesian updating and simulation of a likelihood (''data'' or X u I ) and consequent posterior distribution p(u) over the outer loop of the Monte Carlo algorithm. It is therefore internally consistent to use these data, which can be considered known or observed, as the basis for our expected net benefit for within-trial patients (popNB trial.j ). The posterior distribution for u, p(ujX u I ) should be used for the expected net benefit of all other patients (popNB out ). This is true even for those patients who will be treated prior to the research reporting (t \ t) because as soon as we make a decision to conduct research, our best estimate of the net benefits for any future patient includes the information provided by the research and therefore the posterior distribution of u.
A major analytical difference between our approach and that taken by McKenna and Claxton 6 is the necessity to move the extrapolation from individual patient EVSI to population EVSI for each group of patients into the outer loop of the Monte Carlo simulation (outlined in the appendix). Without taking this step, which is a central characteristic of ENPVSI as we have defined it, uncertainty around the time taken for proposed research would be ignored. Meaningful differences in value of information would result where time for research is partially dependent on prior estimates for the effectiveness of an intervention.
The framework for implementation of ENPVSI outlined here is generalizable to instances in which the likelihood for the proposed data is conjugate with their independent prior distributions, such that it is possible to specify posterior distributions in closed form. Additional nested simulations would be one way in which this requirement could be relaxed but would lead to further substantial computational burden.
In this article we only consider the gold standard method for EVSI calculation as specified by Ades and others, 5 whereby an inner Monte Carlo simulation is nested within an outer loop. In doing so, implementation required considerable computer processing time. Our exemplar calculations could only be completed within a sensible time frame by using a high-performance parallel processing cluster (ARC1, Leeds Node of the White Rose High Performance Computing Grid) implemented using the R statistical programming language. 13 For simple models, the requirement for an inner loop, with resultant high computational burden, may by side-stepped by assumptions of model linearity or multilinearity. 14 Our example illustrates the methodological advances proposed by this article. We have attempted to keep this example simple in order to illustrate our message clearly. For practical application there would undoubtedly be a requirement to expand on the work presented here. For example, our calculation of t, the time for research to report, does not currently take into account the time for trial setup and analysis. We also do not take the next essential step, which would be to calculate the Expected Net Benefit of Sampling, which takes account of the costs of research, which will invariably be related to t, and subtracts these from the EVSI. The methods for doing this are clearly described by others. 1, 9 Equally, we do not take account of the expected value of perfect implementation, which considers that not all research evidence is implemented into clinical practice. 15 In conclusion, expected value of information and Bayesian decision theory offers an explicit framework for rational reimbursement decision making and efficient research design. When it is applied to specific research designs, consideration of treatment allocation to different groups of patients and the time taken for information to be obtained will meaningfully influence the calculation of EVSI. The updated framework presented here will require further development to consider complex or multiparameter research design proposals and issues such as forecasted prices and the introduction of alternative technologies over the lifetime of a new intervention.
APPENDIX
General Monte Carlo sampling algorithm for calculation of population ENPVSI (adapted from Ades and others 5 ) u I 5parameters of interest here assumed independent of u c I À Á
First record the net benefit of an optimal decision based on current information. Then define a proposed piece of research from which data X uI will be collected to inform u I . B4. Calculate expected net benefits for each strategy j given the likelihood X ðiÞ uI , evaluated at its mean, using an inner Monte Carlo simulation loop. B5. Find the strategy j maximizing expected net benefit for simulation i based on B3. B6. Draw a sample from the distribution of time to trial reporting (t) using X ðiÞ uI .
B7. Using the expected net benefit given the mean of the likelihood X ðiÞ uI (B4), allocate net benefit to patients allocated to trial arms for each strategy j for each time interval up to t, discounted. B8. Using the posterior expected net benefits (B3), record the population net benefit for patients not in trial for time intervals prior to time t who receive the optimal strategy j given a decision based on the prior expected net benefits up to time t, discounted. B9. Record the population net benefit for the optimal strategy j given a decision based on the posterior expected net benefits using the discounted population for each time interval after the trial has reported. B10. Record the sum of the expected net benefits over all groups in B7, B8, and B9. A2. Find the average of the population expected net benefits (B10), over the N simulations. This is the population expected value of a decision based on sample information. A3. Subtract from this the population expected value of a decision based on current information to give the ENPVSI.
